Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates (Q40773199)

23 September 2017

title

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates (English)

1 reference

23 September 2017

Lee SA

1

1 reference

23 September 2017

Orque R

2

1 reference

23 September 2017

Escarpe PA

3

1 reference

23 September 2017

Peterson ML

4

1 reference

23 September 2017

Good JW

5

1 reference

23 September 2017

Zaharias EM

6

1 reference

23 September 2017

Berman PW

7

1 reference

23 September 2017

Sheppard HW

8

1 reference

23 September 2017

Shibata R

9

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

23 September 2017

1 reference

23 September 2017

volume

20

1 reference

23 September 2017

issue

3-4

1 reference

23 September 2017

page(s)

563-576

1 reference

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Annual updated survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Statistical Issues in the Design of HIV Vaccine Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Comparing methods for calculating confidence intervals for vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Prevention of HIV infection by passive immunization with HIV immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

A preliminary evaluation of five HIV antigen detection assays

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Flow cytometric indirect immunofluorescence assay with high sensitivity and specificity for detection of antibodies to human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Envelope sequences of two new United States HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and C

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral Strains

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Genetic variants of HIV-1 in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Designing CD4 immunoadhesins for AIDS therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Measuring vaccine-induced HIV neutralization: report of a workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900334-6

7 January 2021

10.1016/S0264-410X(01)00334-6

Identifiers

DOI

1 reference

23 September 2017

1 reference